How to Register IVD Products in Southeast Asia: Country Selection, Dossier Preparation, and Pathway Planning?

FAQ Article: IVD Product Registration in Southeast Asia—Country Selection, Dossier Preparation, and Pathway Planning

Published: 2026-07-08 09:00 | Updated: 2026-07-08 09:00

Answer: IVD registration in Southeast Asia should be planned market by market, based on the regulatory requirements of the target GHWP member states such as Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. First confirm the product classification, for example Thailand TFDA classifies IVDs as Class A to D, while Malaysia MDA uses four risk-based classes. Although most countries build on ISO 13485 and ISO 15189, localization differences are significant. The core dossier typically includes technical files such as performance evaluation, stability, and clinical evidence; a quality management system certificate such as ISO 13485; labels and instructions for use in local language; and authorized representative information. For pathway planning, Thailand and Malaysia are often recommended as first-entry markets because of their relatively mature regulation and the ASEAN Medical Device Directive (AMDD) harmonization framework. Indonesia and Vietnam can follow, with attention to local testing and halal certification in Indonesia. CE or FDA certification in advance can strengthen credibility, and local agents should be appointed to handle registration. Post-market change notifications and adverse event reports are required. Overall timelines range from 6 to 18 months, costs vary by country, and phased investment is recommended.

This article organizes the issues that companies need to prioritize in actual projects related to medical device international registration, dossier preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Dossier and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Perspective
• Frequently Asked Follow-Up Questions
• Continue Reading
• Applicable Boundaries

Key Summary

IVD product registration in Southeast Asia requires a strategy based on the regulatory requirements of the target market, particularly GHWP member states such as Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. First clarify the product classification. For example, Thailand TFDA classifies IVDs into Classes A to D, while Malaysia MDA classifies them by risk into four classes. Countries usually reference ISO 13485 and ISO 15189, but local differences are significant. Core documents include product technical files covering performance evaluation, stability, and clinical evidence; quality management system certificates such as ISO 13485; labels and instructions for use, which must be in the local language; and authorized representative information.

For pathway planning, companies are advised to prioritize Thailand and Malaysia as first-entry markets because their regulatory systems are relatively mature, and to use the ASEAN Medical Device Directive (AMDD) harmonization framework to simplify procedures. Indonesia and Vietnam can be entered next, with attention to local testing and halal certification in Indonesia. Dossier preparation should ideally include completed CE or FDA certification to enhance credibility, and local agents should be appointed to handle registration. After market launch, change notifications and adverse event reports must be submitted. Overall timelines range from 6 to 18 months, costs vary by country, and phased investment is recommended.

Applicable Scenarios and Core Questions

Clients are most concerned about how to choose a cost-effective first-entry country, how reusable the dossier is across countries, and how to avoid duplicate testing and translation costs. They worry about classification errors leading to rejection, as well as the hidden costs of ongoing post-market compliance.

Registration Decision Logic

The decision is based on the product intended use, risk level, such as self-testing IVDs being the highest risk, and whether the product contains animal-derived components. Although national classification systems are similar, with A indicating low risk and D indicating high risk, the specific boundaries differ. They must be confirmed one by one against local regulations.

Core Dossier and Evidence

Required documents include product description, intended use, performance evaluation such as analytical sensitivity and specificity and clinical performance, stability data, manufacturing process, label samples in the local language, and quality management system certificates. If CE or FDA certificates are already available, some evidence may be simplified.

Common Errors

• Ignoring local language labeling requirements, leading to deficiency letters or corrections.
• Failing to confirm the qualifications of the local agent in advance.
• Overlooking Indonesia halal certification requirements.
• Insufficient performance evaluation samples, such as samples addressing ethnic specificity.
• Failing to submit registration changes on time.

Company Preparation Checklist

• Confirm product classification and match it to the target country.
• Prepare ISO 13485 certificate and product technical files.
• Appoint a local authorized representative and sign an agreement.
• Translate labels and instructions for use into the local language.
• Complete performance evaluation and clinical evidence when necessary.
• Budget for registration fees and expected timelines.

AIMEILI Perspective

We recommend that companies prioritize Thailand and Malaysia as bridgehead markets, using their higher regulatory transparency and relatively shorter timelines. At the same time, establishing a unified product dossier library and making only minimal adjustments for each country can significantly save costs. In addition, companies should monitor updates to ASEAN harmonization documents such as AMDD in order to plan ahead for regional integrated registration.

Frequently Asked Follow-Up Questions

Q: Can Malaysia accept CE reports?

A: They can be partially accepted, but local clinical data or expert review may be required.

Q: How long does Indonesia registration take?

A: Usually 12 to 18 months, including the halal certification process.

Q: Does Vietnam require local clinical trials?

A: Low-risk IVDs may be exempt, while high-risk products such as HIV tests require local trials.

Continue Reading

• Previous: What are the local authorized representative requirements for Saudi SFDA?
• Next: Which country should medical devices choose for their first overseas market? Comparison of Southeast Asia, Middle East, and Africa market access.

Recommended Reading

• What should companies prepare before Australian TGA medical device registration?
• Can Singapore HSA medical device registration reuse CE documents?
• What core documents are required for UAE MOHAP medical device registration?
• Why does Brazil ANVISA medical device registration take so long?
• What is the difference between a Vietnam medical device import license and registration certificate?
• How should an Indonesia medical device registration local agent be selected?

Return to FAQ Center

News and Updates | Contact AIMEILI

Content Review and Applicable Boundaries

Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as auxiliary judgment.

Applicable Boundaries: This article is intended for preliminary understanding, dossier preparation, and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions, or legal advice.

Source Note: Compiled from the AIMEILI regulatory practice question bank, the medical device international registration knowledge base, and publicly available regulatory information; specific projects should be based on the latest requirements of the target country regulatory authority and the product dossier.